← Leaderboards
Mark T Dransfield
University Of Alabama At Birmingham
$4,801,118
Attributed
$7,646,426
Total exposure
6
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.2M · FY2007–22$5M$3.8M$2.5M$1.3M$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$8,486,876 · 7
By mechanism
UH3$4,466,327 · 1
P30$1,610,863 · 2
U10$746,740 · 1
UG3$624,194 · 1
R34$600,095 · 1
K24$438,657 · 1
Top collaborators
- Steven Mark Rowe3 shared
- Inmaculada Aban2 shared
- Gary R Cutter2 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Amit Gaggar$7,818,359
- Steven Mark Rowe$18,443,646
- Inmaculada Aban$2,481,905
- Kristopher R. Genschmer$1,930,500
Others in their field
Top investigators on “Randomized”
- James Dennis Neaton · Northwestern University$305,243,252
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$292,521,996
- Lawrence Corey · Fred Hutchinson Cancer Center$292,521,996
- Marian Ewell · The Emmes Company, Llc$278,931,253
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$199,647,509
- Beth Baseler · Leidos Biomedical Research, Inc.$194,920,310
Research focus
RandomizedChronic Obstructive Airway DiseaseCause Of DeathResearch PersonnelRespiratory PhysiologyLungPlacebosPharmaceutical PreparationsClinical TrialsBiological MarkersSafetyResponseDirect CostsDisease ProgressionTrainingUnited StatesLung DiseasesDouble-Blind MethodCystic FibrosisMorbidity - Disease RateBaseDyspneaRespiratoryMortality
Grant awards (15)
UAB Mentoring Program in COPD Patient Oriented Research$86,187
K24 · FY2022 · HL · contact PI
AZD9688: A First in Class Disease Modifying Therapy to Treat Alpha-1 Antitrypsin Deficiency a Genetically Linked Orphan Disease$896,654
UH3 · FY2021 · TR · contact PI
UAB Mentoring Program in COPD Patient Oriented Research$86,187
K24 · FY2021 · HL · contact PI
A Multicenter Randomized, Double-blind, Phase 2, Placebo Controlled Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease$350,188
P30 · FY2020 · DK · contact PI
UAB Mentoring Program in COPD Patient Oriented Research$88,617
K24 · FY2020 · HL · contact PI
AZD9688: A First in Class Disease Modifying Therapy to Treat Alpha-1 Antitrypsin Deficiency a Genetically Linked Orphan Disease$1,815,951
UH3 · FY2019 · TR · contact PI
UAB CF Research and Translation Core Center$840,450
P30 · FY2019 · DK
A Multicenter Randomized, Double-blind, Phase 2, Placebo Controlled Study to Determine the Safety and Efficacy of Ivacaftor (VX-770) for the Treatment of Chronic Obstructive Pulmonary Disease$420,225
P30 · FY2019 · DK · contact PI
UAB Mentoring Program in COPD Patient Oriented Research$88,833
K24 · FY2019 · HL · contact PI
AZD9688: A First in Class Disease Modifying Therapy to Treat Alpha-1 Antitrypsin Deficiency a Genetically Linked Orphan Disease$1,753,722
UH3 · FY2018 · TR · contact PI
AZD9688: A First in Class Disease Modifying Therapy to Treat Alpha-1 Antitrypsin Deficiency a Genetically Linked Orphan Disease$624,194
UG3 · FY2018 · TR · contact PI
UAB Mentoring Program in COPD Patient Oriented Research$88,833
K24 · FY2018 · HL · contact PI
A Pilot Study of the Effect of the CFTR Potentiator Ivacaftor in COPD (P-TOPIC)$303,126
R34 · FY2016 · HL
A Pilot Study of the Effect of the CFTR Potentiator Ivacaftor in COPD (P-TOPIC)$296,969
R34 · FY2015 · HL
UAB/BVAMC Clinical Center in COPD$746,740
U10 · FY2007 · HL · contact PI